When would you use PSMA PET over conventional imaging for prostate cancer?

Would you use it for initial staging or at time of biochemical recurrence?

Answer from: Medical Oncologist at Academic Institution

So far, most (but not all) prospective data for molecular imaging has been obtained in the setting of biochemical recurrence and that is where I have used it most outside of trials.In the primary disease setting, some trials examined the utility to detect nodal and distant disease (like OSPREY publi...

Comments

Radiation Oncologist at Community Health Network
I agree. But also order it in the setting of suspi...

Radiation Oncologist at Washington University School of Medicine
2022 NCCN guidelines state “PSMA PET-CT or P...

Medical Oncologist at ZNA Jan Palfijn
Am I right in commenting that there is no proven b...

Radiation Oncologist at Cancer Care Group
We recently began using PYLARIFY, in accordance wi...

Answer from: Radiation Oncologist at Academic Institution

If money were no object, the short answer is, every time, in the setting of recurrence or in the setting of high risk or very high risk disease based on the ProPSMA trial (Hofman et al., PMID 32209449) and the Appropriate Use Criteria put out by the Society for Nuclear Medicine and Molecular Im...

Comments

Radiation Oncologist at Physician Health Partners
If positive, it will change the Rx.

Please select the option that best describes you:

When would you use PSMA PET over conventional imaging for prostate cancer?

Related Questions